Donald Debrakeleer, DO
Urogynecology and Reconstructive Pelvic Surgery · Pennington, NJNPI 1427049311
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Caldera Medical, Inc accounts for 62.6% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2022 at $18,388 and has fallen 93.6% since, to $1,176 in 2025. Among urogynecology and reconstructive pelvic surgery clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 257 payments — averaging $138.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Caldera Medical, Inc$22K
- Axonics, Inc.$4K
- Merck$3K
- Bluewind Medical$1K
- Medtronic$1K
- Boston Scientific$529
- plus $4K from 32 others
Across 13 payments — averaging $1338.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coloplast$15K
- Sumitomo Pharma America, Inc.$2K
What the payments were for
- Consulting fees$21,12459%
- Speaking & faculty fees$3,3759%
- Travel & lodging$3,90111%
- Food & beverage$6,88719%
- Education$1781%
- Gifts$1951%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Caldera Medical, Inc | 25 | $22,325 |
| Axonics, Inc. | 35 | $3,500 |
| Merck | 7 | $3,485 |
| Bluewind Medical | 11 | $1,073 |
| Medtronic(2 entities) | 23 | $1,045 |
| Boston Scientific | 9 | $529 |
| AbbVie(2 entities) | 27 | $468 |
| Coloplast | 18 | $419 |
| Sumitomo Pharma America, Inc. | 16 | $358 |
| Intuitive Surgical | 2 | $342 |
| Aspira Women's Health Inc | 3 | $255 |
| Astellas Pharma US Inc | 9 | $208 |
| Therapeuticsmd, Inc. | 11 | $187 |
| Amgen | 6 | $180 |
| Urovant Sciences Inc | 7 | $179 |
| Evofem Biosciences, Inc. | 9 | $173 |
| Si-bone, Inc. | 3 | $97 |
| Coopersurgical, Inc. | 3 | $84 |
| AMAG Pharmaceuticals, Inc. | 5 | $68 |
| Lupin Inc. | 1 | $65 |
| Gynesonics, Inc. | 1 | $62 |
| Johnson & Johnson | 2 | $53 |
| Olympus America Inc. | 2 | $53 |
| 180 Medical, Inc. | 2 | $50 |
| Davol Inc. | 1 | $49 |
| Mayne Pharma Commercial LLC | 3 | $42 |
| Atricure, Inc. | 1 | $41 |
| Hologic Sales And Service, LLC | 2 | $40 |
| Millicent US Inc | 2 | $36 |
| Heron Therapeutics, Inc. | 2 | $34 |
| Myovant Sciences Inc. | 1 | $31 |
| Pfizer | 2 | $28 |
| Covidien LP | 1 | $21 |
| Bayer | 1 | $21 |
| Organon | 1 | $19 |
| Avion Pharmaceuticals | 1 | $14 |
| BD | 1 | $13 |
| Mission Pharmacal Company | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,660 in reported general payments places this provider in the 90th percentile of 35 urogynecology and reconstructive pelvic surgery providers in New Jersey.
See all urogynecology and reconstructive pelvic surgery providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 155 | $127,096 |
| MyrbetriqMirabegron | 15 | $9,060 |
| Estradiol | 174 | $8,343 |
| NitrofurantoinNitrofurantoin Macrocrystal | 15 | $1,156 |
| Clobetasol Propionate | 17 | $1,154 |
| Solifenacin Succinate | 13 | $1,134 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 68 | $833 |
| Nystatin-TriamcinoloneNystatin/Triamcinolone Acet | 17 | $390 |
| Nystatin | 18 | $256 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $99 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 25 | $84 |
| Fluconazole | 20 | $72 |
| Oxycodone Hcl | 12 | $27 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $358 | $127,096155 claims |
| Astellas Pharma US IncMyrbetriq | $208 | $9,06015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 35 urogynecology and reconstructive pelvic surgery providers in New Jersey.
Other urogynecology and reconstructive pelvic surgery in Pennington
- Nina BhatiaManalapan$77K
- Debra FromerHackensack$50K
- Uzma ChaudhryTrenton$14K
- Alexander BergerCherry Hill$14K
- Kristene WhitmoreCherry Hill$13K
- Betsy GreenleafHowell$11K
- Sandy NosseirMarlton$11K
- Gary MironeCape May Court House$9K
- Anna PancheshnikovVoorhees$8K
- Patricia ZahnerMoorestown$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.